Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Viking Therapeutics Inc.

Developing “undervalued” assets for metabolic, endocrine disorders

This article was originally published in Start Up

Executive Summary

Viking Therapeutics Inc. has clinical-stage compounds for disorders amplifying as the world's population ages. The start-up’s first drug candidate is a potential treatment for people recovering from hip fracture; the second shows promise for fatty liver disorders that are spreading as the western diet does.


Related Content

Viking Flexes Its Muscles Ahead Of Partnering Talks


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts